To investigate potential changes in the lung microenvironment that preceded the delayed lung cancer growth induced by S100A8 treatment, mice with LLC cancers were given three intranasal treatments of S100A8 (Group 1, S100A8 + LLC) as outlined in Figure 1G, and whole lungs collected at midpoint of survival (Day 10). Here, S100A8 is linked to lung cancer.